A New Hope
The U.S. Food and Drug Administration (FDA) has taken a move in the management of Alzheimer’s disease by approving a drug known as Kisunla (donanemab-azbt).
Kisunla focuses on patients diagnosed with early-stage Alzheimer’s, all in a bid to attain stabilization of disease progression by targeting amyloid plaques in the brain, as per the FDA.
How it Works – Targeting Amyloid Plaques
Kisunla serves as an amyloid-directed antibody that targets a toxic type of amyloid-beta. This protein is assumed to be involved in neurotoxicity and cognitive deterioration in the course of Alzheimer’s disease.
Alzheimer’s is characterized by the amyloid plaques formed through the accumulation of aggregated amyloid-beta peptides in the brain due to lack of clearance by the body. According to Brightfocus, this is believed to be the main cause of the development and progression of the disease. Kisunla helps the body to exterminate these plaques through improved targeting in the immune system.
Used intravenously and given at a four-weekly interval, Kisunla’s initial dosing is three 700-milligram doses with one 400-milligram maintenance dose. Long-term clinical trials showcased patients who fell to a level where their amyloid plaque levels were no longer visible by scan, in which they were approved to end the treatment. The ability to end treatment based on improvement is a major advantage of Kisunla, may help lower long-term treatment costs, and reduce unnecessary exposure to the medication.
Efficiency with Clinical Trials
This approval was made based on clinical data, and more specifically from Phase III data in the TRAILBLAZER-ALZ 2 trial through Eli Lilly and Company.
A total of 2736 participants were recruited in eight countries, and all patients had early Alzheimer’s symptoms. Kisunla was found statistically significant in the study by demonstrating improvement of study participants over 76 weeks as compared to the placebo group in the various cognitive and functional assessment scales. These were the Integrated Alzheimer’s Disease Rating Scale (iADRS), the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog13), and the Alzheimer’s Disease Cooperative Study – Instrumental Activities of Daily Living (ADCS-iADL) scale.
Among the study’s outcomes, one conclusion was that patients can leave the treatment once amyloid plaques have dropped to undetectable levels. Roughly half of the patients (47%) in the study had low amyloid plaque levels to potentially stop therapy on a one-year follow-up and 69% of the patients at a 1.5-year follow-up.
This may translate to a shift in the management of Alzheimer’s disease, in which the patient does not have to be subjected to lifelong treatment, lowering the economic and social implications of the condition.
The Risks and Safety
Nevertheless, the success of the Kisunla drug bears considerable safety concerns that accompany its approval. Some of the participants in the trials experienced ARIA, a well-known side effect in amyloid-targeting drugs. Moreover, exhibiting symptoms such as a temporary swelling in the brain that goes away afterward. But in some instances, ARIA can be severe or even fatal according to the FDA. Patients with ApoE ε4 gene are more likely to develop ARIA including those who are homozygotes of the gene (carrying two copies).
Physicians are mandated to assess patients for ARIA using magnetic resonance imaging (MRI) pre-treatment as well as consistent monitoring during therapy. Some warning signs are headaches, dizziness, nausea, stumbling, confusion, and blurred vision.
Costs, Prescriptions, and Availability
The drug needs to be used cautiously and only after a proper selection of the patient coupled with regular monitoring to ensure that detrimental complications do not arise. The other factor is cost, which is also important. It has been estimated that the total cost of treatment in six months ranges to about $12,522.
Each vial costs approximately $696, with the payment length dependent on the duration of use. Medicare has since made an option to sponsor Kisunla and diagnostic tests to be carried out to establish the eligibility of patients. Furthermore, the company that produces Kisunla, Eli Lilly & Co., provides a support program to those who want to apply for the drug and can support themselves adequately enough to justify costs for the treatment.
What does all this mean?
In cases regarding Alzheimer’s, the approval of Kisunla has been received with positivity. It not only offers patients with early-stage Alzheimer’s an extra form of treatment, but it also emphasizes early diagnosis of the disease. In delaying the progression of Alzheimer’s, Kisunla provides patients and their families with an “invaluable gift of time” according to its advocates.
Anne White, the Executive Vice President spoke about treatment outcomes provided by Kisunla for the patients with early symptoms, pointing to the necessity of a treatment in its early stage. Thus, having received traditional FDA approval as the second anti-amyloid therapy, Kisunla may help progress the anti-Alzheimer’s treatment further according to BrightFocus.
Continuation for the Future
The approval of Kisunla also means that a new avenue opens for further research and development of the treatment.
Kisunla remains in the development stage as Eli Lilly conducts many clinical trials. The TRAILBLAZER-ALZ 3 study aimed at mitigating the development of symptomatic Alzheimer’s in patients with early biomarker indicators of the disease according to the company behind the scenes: Eli Lilly & Co. It is a continued investigation to widen the knowledge of ARIA with the help of advanced MRI, blood markers, and various dosing methods.
The approval of Kisunla showcases the new approach for the management of Alzheimer’s disease. Even though targeting amyloid-beta is a major advancement, other aspects of the disease, including tau protein aggregation and neuroinflammation are also being considered by the researchers. Substances with therapeutic characteristics increase as the number of therapies for the disease expands, so that a combination strategy for Alzheimer’s is possible.
The Next Frontier in Alzheimer’s and Neurodegenerative Disorders
The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals, this company could greatly affect the quality of life in early-stage Alzheimer’s patients.
It does not end here, however: it is necessary to propose the development of a series of subject teaching and learning frameworks. This approval comes with research that continues to be done, vigilant supervision of the effects of drugs and medicines, and commitment to dealing with the issues of Alzheimer’s in bringing a new fight to the disease.
